
EquitySector - HealthcareVery High Risk
Regular
NAV (28-Sep-26)
Returns (Since Inception)
Fund Size
₹125 Cr
Expense Ratio
2.58%
ISIN
INF663L01Z52
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
06 Dec 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+25.37%
+18.68% (Cat Avg.)
Since Inception
+10.65%
— (Cat Avg.)
| Equity | ₹118.35 Cr | 94.57% |
| Others | ₹6.8 Cr | 5.43% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Divi's Laboratories Ltd | Equity | ₹13.57 Cr | 10.85% |
| Sun Pharmaceuticals Industries Ltd | Equity | ₹13.43 Cr | 10.74% |
| Torrent Pharmaceuticals Ltd | Equity | ₹11.09 Cr | 8.86% |
| Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹7.21 Cr | 5.76% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹6.21 Cr | 4.96% |
| Ajanta Pharma Ltd | Equity | ₹6.04 Cr | 4.83% |
| Manipal Health Enterprises Ltd | Equity | ₹5.16 Cr | 4.12% |
| Mankind Pharma Ltd | Equity | ₹5.09 Cr | 4.07% |
| Rubicon Research Ltd | Equity | ₹5.02 Cr | 4.01% |
| Dr. Lal PathLabs Ltd | Equity | ₹4.92 Cr | 3.93% |
| Neuland Laboratories Ltd | Equity | ₹4.08 Cr | 3.26% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹3.95 Cr | 3.15% |
| Navin Fluorine International Ltd | Equity | ₹3.81 Cr | 3.04% |
| Aster DM Quality Care Ltd Ordinary Shares | Equity | ₹3.62 Cr | 2.89% |
| Abbott India Ltd | Equity | ₹3.54 Cr | 2.83% |
| Sai Life Sciences Ltd | Equity | ₹3.18 Cr | 2.54% |
| Cipla Ltd | Equity | ₹2.79 Cr | 2.23% |
| Pfizer Ltd | Equity | ₹2.65 Cr | 2.12% |
| Anthem Biosciences Ltd | Equity | ₹2.45 Cr | 1.96% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹2.22 Cr | 1.77% |
| Global Health Ltd | Equity | ₹2.15 Cr | 1.72% |
| Zydus Lifesciences Ltd | Equity | ₹1.89 Cr | 1.51% |
| Lupin Ltd | Equity | ₹1.78 Cr | 1.42% |
| ICICI Lombard General Insurance Co Ltd | Equity | ₹1.75 Cr | 1.40% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹1.5 Cr | 1.20% |
| Fortis Healthcare Ltd | Equity | ₹1.37 Cr | 1.10% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹1.07 Cr | 0.86% |
| Orchid Pharma Ltd | Equity | ₹1 Cr | 0.80% |
| Gland Pharma Ltd | Equity | ₹0.92 Cr | 0.73% |
| Lenskart Solutions Ltd | Equity | ₹0.89 Cr | 0.71% |
| Ipca Laboratories Ltd | Equity | ₹0.63 Cr | 0.51% |
| Sagility Ltd | Equity | ₹0.58 Cr | 0.46% |
| Net Receivables / (Payables) | Cash | ₹-0.41 Cr | 0.33% |
Large Cap Stocks
32.67%
Mid Cap Stocks
28.18%
Small Cap Stocks
29.60%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹112.79 Cr | 90.13% |
| Basic Materials | ₹3.81 Cr | 3.04% |
| Financial Services | ₹1.75 Cr | 1.40% |
Standard Deviation
This fund
--
Cat. avg.
16.08%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.94
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.63
Higher the better
Since January 2025
Since January 2025
Since January 2025
Since January 2025
ISIN INF663L01Z52 | Expense Ratio 2.58% | Exit Load No Charges | Fund Size ₹125 Cr | Age 1 year 9 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹27,561 Cr
Address
Nirlon House, 2nd Floor, Mumbai, 400 030
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments